Suppr超能文献

男性和女性尿液中非结合型19-去甲-脱氧皮质酮的来源及注入放射性标记的19-去甲-脱氧皮质酮的代谢情况。

Origin of urinary nonconjugated 19-nor-deoxycorticosterone and metabolism of infused radiolabeled 19-nor-deoxycorticosterone in men and women.

作者信息

Casey M L, Guerami A, Milewich L, Gomez-Sanchez C E, MacDonald P C

出版信息

J Clin Invest. 1985 Apr;75(4):1335-8. doi: 10.1172/JCI111834.

Abstract

It is known that 19-nor-deoxycorticosterone (19-nor-DOC) is a potent mineralocorticosteroid that is present in urine of rats and humans in a free, i.e., nonconjugated, form. In some forms of hypertension in rats, the levels of free 19-nor-DOC in urine are increased compared with those in urine of normotensive animals. Yet, despite the potential importance of this mineralocorticosteroid in the pathogenesis of certain forms of hypertension, little is known of its site of origin or metabolism. In the present investigation, we evaluated the metabolism of intravenously infused [3H]19-nor-DOC and the possibility that 19-nor-DOC was formed from plasma DOC. We found that the metabolism of [3H]19-nor-DOC infused intravenously in men and women was similar to that of DOC with important exceptions. The majority of the radiolabeled urinary metabolites of intravenously infused [3H]19-nor-DOC were excreted in urine as glucuronosides. Little radioactivity, infused as [3H]19-nor-DOC, was recovered in urine as nonconjugated or sulfoconjugated steroids. There was no free radiolabeled 19-nor-DOC in urine after the simultaneous infusion of [3H]19-nor-DOC and [14C]DOC. A major metabolite of [3H]19-nor-DOC in urine was 19-nor-DOC-21-glucuronoside, whereas little or no intravenously infused radiolabeled DOC was excreted as radiolabeled DOC-glucuronoside. We also found that intravenously infused [14C]DOC was not converted to urinary [14C]19-nor-DOC (glucuronoside) and that other tritium-labeled metabolites of infused [3H]19-nor-DOC contained no carbon-14. The production rate of 19-nor-DOC, computed from the specific activity of urinary 19-nor-DOC (glucuronoside), in one normal man was 16 micrograms/d and in the two women of this study, it was 10 micrograms/d. These findings are supportive of the proposition that free urinary 19-nor-DOC is not formed from plasma DOC; it may be formed in kidney from a precursor other than DOC or it may be formed nonenzymatically in kidney or urine from a precursor such as 19-oic-DOC.

摘要

已知19-去甲脱氧皮质酮(19-nor-DOC)是一种强效盐皮质激素,以游离形式(即非结合形式)存在于大鼠和人类尿液中。在大鼠的某些高血压形式中,尿液中游离19-nor-DOC的水平与正常血压动物尿液中的水平相比有所升高。然而,尽管这种盐皮质激素在某些形式的高血压发病机制中具有潜在重要性,但其起源部位或代谢情况却知之甚少。在本研究中,我们评估了静脉注射[3H]19-nor-DOC的代谢情况以及19-nor-DOC由血浆DOC形成的可能性。我们发现,静脉注射[3H]19-nor-DOC在男性和女性中的代谢情况与DOC相似,但有重要例外。静脉注射[3H]19-nor-DOC的大多数放射性标记尿代谢产物以葡糖醛酸苷形式排泄到尿液中。作为[3H]19-nor-DOC注入的放射性很少以非结合或硫酸结合类固醇形式在尿液中回收。同时注射[3H]19-nor-DOC和[14C]DOC后,尿液中没有游离的放射性标记19-nor-DOC。尿液中[3H]19-nor-DOC的主要代谢产物是19-nor-DOC-21-葡糖醛酸苷,而静脉注射的放射性标记DOC很少或没有以放射性标记DOC-葡糖醛酸苷形式排泄。我们还发现,静脉注射的[14C]DOC不会转化为尿液中的[14C]19-nor-DOC(葡糖醛酸苷),并且注入的[3H]19-nor-DOC的其他氚标记代谢产物不含碳-14。根据一名正常男性尿液中19-nor-DOC(葡糖醛酸苷)的比活性计算出的19-nor-DOC生成率为16微克/天,在本研究的两名女性中为10微克/天。这些发现支持了游离尿19-nor-DOC不是由血浆DOC形成的观点;它可能在肾脏中由DOC以外的前体形成,或者可能在肾脏或尿液中由诸如19-氧代-DOC的前体非酶促形成。

相似文献

2
5
Deoxycorticosterone sulfate biosynthesis in human fetal kidney.
J Clin Endocrinol Metab. 1981 Nov;53(5):990-6. doi: 10.1210/jcem-53-5-990.
8
Urinary free 19-nor-deoxycorticosterone and deoxycorticosterone in human hypertension.
J Clin Endocrinol Metab. 1985 Feb;60(2):234-8. doi: 10.1210/jcem-60-2-234.
9
Plasma and urinary 19-nor-deoxycorticosterone in 17 alpha-hydroxylase deficiency syndrome.
J Clin Endocrinol Metab. 1984 Nov;59(5):1011-5. doi: 10.1210/jcem-59-5-1011.

本文引用的文献

2
Sodium retaining activity of 19-nor-steroids in adrenalectomized rats.
Proc Soc Exp Biol Med. 1957 Mar;94(3):444-7. doi: 10.3181/00379727-94-22972.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验